GIR PROJECTS
Take a look to our ongoing and previous projects
ONGOING GIR PROJECTS
⊗
GRANTED IN 2022
INTERNATIONAL
NATIONAL
AUTONOMIC
PRIVATE FUNDING
OTHER PROJECTS
GRANTED IN 2021
⊗
GRANTED IN 2022
Ayudas para organización de Jornadas y Congresos UDC: 1.500€
– Título: Medicina personalizada en la artrosis: inteligencia artificial aplicada al diagnóstico de OA de rodilla rápidamente progresiva
- Expediente: PI22/01155
- Entidad financiadora: Proyectos de Investigación en Salud, AES2022, ISCIII
- Duración: 2023-2025
- Cuantía: 177.870€
- Investigador principal: Francisco J Blanco.
– Título: Epi-OSTEOARTROMED: Búsqueda de biomarcadores epigenéticos en la prevención de artrosis con la dieta mediterránea
- Expediente: PI22/01165
- Entidad financiadora: Proyectos de Investigación en Salud, AES2022, ISCIII
- Duración: 2023-2025
- Cuantía: 232.320€
- Investigador principal: María del Carmen de Andrés González
– TÍTULO: Clinical validation of OPTIBIO algorithm to predict persistent remission in rheumatoid arthritis patients treated with biological therapy. (REMRABIT- plus)
- EXPEDIENTE: PMP22/00101
- CONVOCATORIA: Proyectos de Investigación de Medicina Personalizada de Precisión, ISCIII
- DURACIÓN: 2023-
- Budget (Ayuda): 1.724.889,617€
- INVESTIGADOR PRINCIPAL: FJ Blanco.
– TÍTULO: Desarrollo de estrategias de visión artificial y aprendizaje automático para la integración de imágenes multimodales con datos clínicos y moleculares en enfermedades reumáticas (SMARTObA)
- EXPEDIENTE: PMPTA22/00115
- Código CDTI: EIS-20220029 (SOL-00155952)
- Convocatoria: Proyectos de medicina personalizada y terapias avanzadas, ISCIII (Convocatoria Conjunta ISCIII-CDTI)
- DURACIÓN: 2022-2014.
- Budget (GIR): 338.195€
- INVESTIGADOR PRINCIPAL: FJ Blanco
– Título: Typing Amyloidosis by Mass Spectrometry (TAMS)
- Entidad financiadora: CIBER-BBN, Early Stage projects
- Duración: 2022-2024
- Investigador principal: Tamara Hermida Gómez
– Título: SAFE-N-MEDTECH (A test bed for assessing nanotechnology-based medical devices)
- Expediente: Grant agreement ID: 814607
- Entidad financiadora: EU, H2020-EU.2.1.3. – INDUSTRIAL LEADERSHIP – Leadership in enabling and industrial technologies – Advanced materials. Topic: DT-NMBP-02-2018 – Open Innovation Test Beds for Safety Testing of Medical Technologies for Health (IA)
- Duración: 01/04/2019-31/03/2023
- Cuantía: 18.466.649,10€ (Total); 968.657,50€ (al Ciber);
- Investigador principal: Departamento de Salud Gobierno Vasco (Coordinador). IP (GIR): Cristina Ruiz Romero.
- Tipo de participación: Colaborador como parte de NanBiosis (Ciber-BBN)
– TÍTULO: Terapias Innovadoras Dirixidas ao Envellecemento Articular e a Artrose Convocatoria: Proyecto de Excelencia. Modalidad C, Gain, Xunta de Galicia
- EXPEDIENTE: IN607D- 2022-11
- DURACIÓN: 2022-2026
- Budget (Ayuda): 115.000 €
- INVESTIGADOR PRINCIPAL: Beatriz Caramés Pérez
– TÍTULO: A Nutriepixenómica como nova ferramenta no tratamento da artrose. Efecto do oleocantal no perfil epixenético dos condrocitos articulares humanos.
- EXPEDIENTE: IN607D- 2022-12
- Convocatoria: Proyecto de Excelencia. Modalidad C, Gain, Xunta de Galicia
- DURACIÓN: 2022-2026
- Budget : 115.000 €
- INVESTIGADOR PRINCIPAL: María del Carmen de Andrés González
- PROYECTOS Y AYUDAS SOLICITADAS EN 2022 (concedidas o no)
INTERNATIONAL
– TÍTULO: Novel Prediction Model for Pain Progression Phenotype in Knee Osteoarthritis patients using Machine Learning
- Expediente: ID#64122119.
- CONVOCATORIA: 3rd Global Awards for Advancing Chronic Pain Research, ADVANCE, financiada por Pfizer Inc y Elli Lilly and Company.
- Importe: 196.168$
- Duración: 15/05/2021-14/05/2024
- INVESTIGADOR PRINCIPAL: Francisco J Blanco.
– TÍTULO: SEN-OA – Targeting senescent cells in osteoarthritis: an innovative therapeutic approach
- Expediente: SEN-OA
- ENTIDAD FINANCIADORA: Foundation for Research in Rheumatology (Foreum)
- DURACIÓN: 2018-2022
- Project Coordinator: Daniele Noel, INSERM, Montpellier, Francia
- IP (WP 4 leader): Beatriz Caramés
- FINANCIACIÓN: 600.000€
- CUANTÍA GRUPO GIR: 93.300 €
– TÍTULO: “EpiOA”
- Proyecto: NIH/NIAMS – OAIBRAC0048
- FUNDING ORGANISATION: NIH (National Institute of Health) USA.
- START DATE AND FINISH DATE: 2021-2022.
- PRINCIPAL INVESTIGATOR: María del Carmen de Andrés González
- BUDGET: Donación de muestras
NATIONAL
-Título: Axudas para a consolidación e estruturación de unidades de investigación
competitivas, modalidade A-Grupos de referencia competitiva
- Expediente: IN607A2021/07
- Entidad financiadora: Axencia Galega de Innovación, Xunta de Galicia
- Duración: 2021-2024
- Cuantía: 400.000€
- Investigador principal: Francisco J Blanco
-Título: Identificación de mutacións de ADNmt específicas da artrose mediante secuenciación masiva para valorar o seu impacto como futuras dianas terapéuticas e no diagnóstico do fenotipo metabólico nunha cohorte de pacientes de Galicia.
- Expediente: IN607D 2021/13
- Entidad financiadora: Axudas para a consolidación e estruturación de unidades de investigación competitivas e outras acción de fomento. Modalidade C-Proxectos de excelencia. Axencia Galega de Innovación, Xunta de Galicia
- Duración: 2021-2025
- Cuantía: 115.000€
- Investigador principal: Ignacio Rego Pérez
TÍTULO: Red en Enfermedades Inflamatorias (REI)
- EXPEDIENTE: RD21/0002/0009
- ENTIDAD FINANCIADORA: Redes de Investigación Cooperativa Orientadas al Resultado en Salud (RICORS), ISCIII
- DURACIÓN: 2022-2024
- CUANTÍA: 109.071,6€
- INVESTIGADOR PRINCIPAL: FJ Blanco
TÍTULO: Osteoartritis: investigación sobre el colágeno y nuevos ingredientes bioactivos
- EXPEDIENTE: IDI-20210747
- ENTIDAD FINANCIADORA: Centro para el Desarrollo Tecnológico Industrial (CDETI). Proyectos I+D Transferencia Cervera. Ministerio de Ciencia e Innovación
- PARTICIPANTES: Ordesa, Leitat, AINIA, Gaiker e INIBIC
- DURACIÓN: 2022-2024
- CUANTÍA: 111.925€
- INVESTIGADOR PRINCIPAL: Beatriz Caramés Pérez
Título: Desarrollo de modelos predictivos clínico-moleculares para personalizar la farmacoterapia en artritis reumatoide
- Expediente: IN607D 2020/10
- Entidad financiadora: Axencia Galega de Innovación, Xunta de Galicia
- Duración: 2020-2024
- Cuantía: 114.870€
- Investigador principal: Cristina Ruiz Romero
Título: Estudio Clínico Fase 2, Randomizado, Controlado por Placebo, Doble-ciego para Evaluar la Eficacia y la Seguridad de Fenofibrato, Fármaco Agonista de Receptores Nucleares PPARa con Actividad senolítica en pacientes con artrosis de rodilla
- Expediente: ICI20/00142
- Entidad financiadora: Proyectos de Investigación Clínica Independiente, ISCIII
- Duración: 2021-2024
- Cuantía: 795.300€
- Investigador principal: FJ Blanco
Título del proyecto: Identificación de mutaciones de ADNmt específicas de artrosis mediante secuenciación masiva para valorar su impacto como futuras dianas terapéuticas y en el diagnóstico de fenotipos “Identification of osteoarthritis-specific mtDNA mutations through massive sequencing to assess its impact as future therapeutic targets and in the diagnosis of phenotypes”
- Expediente: PI20/00614
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII
- Duración: 2021-2023
- Cuantía de la subvención: 196.020 (121.000; 37.510; 37.510)
- Investigador principal: Ignacio Rego Pérez
Título del proyecto: Agonistas de PPARa como tratamiento modificador de la enfermedad para la Artrosis “Advancing PPARα agonists as a Disease-Modifying Therapy for Osteoarthritis”
- Expediente: PI20/00643
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII
- Duración: 2021-2023
- Cuantía de la subvención: 117.370 (66.550; 25.410; 25.410)
- Investigador principal: Beatriz Caramés Pérez
Título del proyecto: Desarrollo de soluciones integradas de analítica predictiva para personalizar la farmacoterapia en pacientes con artritis reumatoide “Development of integrated predictive analytics solutions to personalize pharmacotherapy in patients with rheumatoid arthritis (BIORESTER-2)”
- Expediente: PI20/00793
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII
- Duración: 2021-2023
- Cuantía de la subvención: 147.620 (96.800; 25.410; 25.410)
- Investigador principal: Cristina Ruiz Romero
Título del proyecto: Nuevas metodologías para la estratificación de pacientes artrósicos (OA) mediante técnicas proteómica, aprendizaje automático y big data. “Novel methodologies for osteoarthritis (OA) patient stratification based on proteomics, machine learning and big data”
- Expediente: PI20/01409
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII
- Duración: 2021-2023
- Cuantía de la subvención: 147.620 (84.700; 37.510; 25.410)Investigador principal: Valentina Calamia
Título: “Estudio farmacogénetico para predecir la respuesta al Tocilizumab en pacientes infectados por SARS-CoV-2”
- Expediente: IN845D 2020/01
- Agencia financiadora: Convocatoria para proxectos de investigación sobre o SARS- CoV-2 e a enfermidade COVID-19, GAIN, Xunta de Galicia.
- Duración: 01/11/2020-31/12/2022
- Importe: 135.530€
- Investigador principal: Ignacio Rego Pérez
Título del proyecto: “Plataformas Innovadoras para Aplicaciones Radiofarmacéuticas" OPTIMAL.
- Expediente: PID2019-111388GB-I00
- Entidad financiadora: Ministerio de Ciencia e Innovación
- Entidades participantes: Universidade da Coruña
- Duración, desde: 1 junio 2020 hasta: 31 mayo 2023
- Cuantía de la subvención: 121.000,00 €
- Investigadores responsables: Dr. Carlos Platas Iglesias y Dr. David Esteban Gómez Número de investigadores participantes: siete; Equipo investigador: Emilia Iglesias Martínez (UDC), Isabel Brandariz Lendoiro (UDC); Equipo de Trabajo: Tamara Hermida Gómez (FPNS), Laura Valencia Matarranz (UVigo), Paulo Pérez Lourido (UVigo).
TÍTULO: EpiOA: Estudio del papel terapéutico de modificadores epigenéticos y nutracéuticos en la artrosis
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. AES 2019-ISCIII.
- DURACIÓN: 2020-2022
- IP: María del Carmen de Andrés
- EXPEDIENTE: PI19/01213
- IMPORTE: 264.082,50 €
Título del proyecto: Eficacia, seguridad y coste-efectividad del metotrexato, adalimumab, o su combinación en uveítis no anterior no infecciosa: un estudio multicéntrico, aleatorizado, paralelo de 3 brazos, con control activo, de fase 3, abierto, con evaluador cegado
- Expediente: ICI19/00020
- Entidad financiadora: Convocatoria de Proyectos de Investigación Clínica Independiente, ISCIII
- Duración: 2020-2023
- IP: Luis Rodríguez Rodriguez, Fundacion Investigacion Biomedica Hospital Clinico San Carlos
- IPs (GIR): Valentina Calamia
- Importe total proyecto: 933.308,27
- Importe grupo: 109.673,44 €
TÍTULO DEL PROYECTO: Clinical validation of new predictive biomarkers for diagnosis and prognosis in osteoarthritis: HPP project.
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. AES 2019-ISCIII.
- Expediente: PI19/01206
- DURACIÓN DESDE: 2020 HASTA: 2022
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García
- IMPORTE: 215.380€
TÍTULO DEL PROYECTO: Red de Inflamación y enfermedades reumáticas (Redes Temáticas de Investigación Cooperativa en Salud)- RIER
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. Expediente RD16/0012/0002.
- DURACIÓN DESDE: 2017 HASTA: 2021 (prórroga hasta 31/12/2022)
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García
- IMPORTE: 168.624,50€
TITULO DEL PROYECTO: Identificación de marcadores genéticos mitocondriales de progresión rápida de artrosis de rodilla mediante técnicas de secuenciación masiva
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/00210
- DURACIÓN: 2018-2020 (prórroga hasta 30/06/2022)
- INVESTIGADOR PRINCIPAL: Ignacio Rego Pérez
- FINANCIACIÓN: 212.657,50 €
TITULO: Identificación y validación de biomarcadores circulares predictivos de respuesta a estrategias de terapia biológica en pacientes con artritis reumatoide (BIO-RESTER)
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/00404
- DURACIÓN: 2018-2020 (prórroga hasta 30/06/2022)
- INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero
- FINANCIACIÓN: 123.420 €
TITULO: Identificación y validación de dianas terapéuticas en la artrosis asociada a diabetes: Papel de la autofagia
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/02059
- DURACIÓN: 2018-2020 (prórroga hasta 30/06/2022)
- INVESTIGADOR PRINCIPAL: Beatriz Caramés Pérez
- FINANCIACIÓN: 111.320 €
TÍTULO DEL PROYECTO: CIBER-BBN (Centro de Investigación Biomédica en Red- Programa Bioingeniería, Biomateriales y Nanomedicina).
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III.
- EXPEDIENTE: CB06/01/0040
- INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero (INIBIC)
- DURACIÓN DESDE: 2006-actualidad
- IMPORTE:
– Título del proyecto: Nuevas metodologías para la estratificación de pacientes artrósicos (OA) mediante técnicas proteómica, aprendizaje automático y big data.. “Novel methodologies for osteoarthritis (OA) patient stratification based on proteomics, machine learning and big data”.
- Expediente: PI20/01409.
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII.
- Duración: 2021-2023.
- Cuantía de la subvención: 147.620 (84.700; 37.510; 25.410).
- Investigador principal: Valentina Calamia.
– Título: “Estudio farmacogénetico para predecir la respuesta al Tocilizumab en pacientes infectados por SARS-CoV-2”
- Expediente: IN845D 2020/01.
- Agencia financiadora: Convocatoria para proxectos de investigación sobre o SARS-CoV-2 e a enfermidade COVID-19, GAIN, Xunta de Galicia.
- Duración: 01/11/2020-31/12/2022.
- Importe: 135.530€
- Investigador principal: Ignacio Rego Pérez.
– Título del proyecto: “Plataformas Innovadoras para Aplicaciones Radiofarmacéuticas” OPTIMAL.
- Expediente: PID2019-111388GB-I00.
- Entidad financiadora: Ministerio de Ciencia e Innovación.
- Entidades participantes: Universidade da Coruña.
- Duración, desde: 1 junio 2020 hasta: 31 mayo 2023.
- Cuantía de la subvención: 121.000,00 €
- Investigadores responsables: Dr. Carlos Platas Iglesias y Dr. David Esteban Gómez.
- Número de investigadores participantes: siete; Equipo investigador: Emilia Iglesias Martínez (UDC), Isabel Brandariz Lendoiro (UDC); Equipo de Trabajo: Tamara Hermida Gómez (FPNS), Laura Valencia Matarranz (UVigo), Paulo Pérez Lourido (UVigo).
– Título del proyecto: Desarrollo de soluciones integradas de analítica predictiva para personalizar la farmacoterapia en pacientes con artritis reumatoide. “Development of integrated predictive analytics solutions to personalize pharmacotherapy in patients with rheumatoid arthritis (BIORESTER-2)”.
- Expediente: PI20/00793.
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII.
- Duración: 2021-2023.
- Cuantía de la subvención: 147.620 (96.800; 25.410; 25.410).
- Investigador principal: Cristina Ruiz Romero.
– Título del proyecto: Agonistas de PPARa como tratamiento modificador de la enfermedad para la Artrosis. “Advancing PPARα agonists as a Disease-Modifying Therapy for Osteoarthritis”.
- Expediente: PI20/00643.
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII.
- Duración: 2021-2023.
- Cuantía de la subvención: 117.370 (66.550; 25.410; 25.410).
- Investigador principal: Beatriz Caramés Pérez.
– Título del proyecto: Identificación de mutaciones de ADNmt específicas de artrosis mediante secuenciación masiva para valorar su impacto como futuras dianas terapéuticas y en el diagnóstico de fenotipos. “Identification of osteoarthritis-specific mtDNA mutations through massive sequencing to assess its impact as future therapeutic targets and in the diagnosis of phenotypes”.
- Expediente: PI20/00614.
- Entidad financiadora: Proyectos de Investigación en Salud, AES2020, ISCIII.
- Duración: 2021-2023.
- Cuantía de la subvención: 196.020 (121.000; 37.510; 37.510).
- Investigador principal: Ignacio Rego Pérez.
– Título: Estudio Clínico Fase 2, Randomizado, Controlado por Placebo, Doble-ciego para Evaluar la Eficacia y la Seguridad de Fenofibrato, Fármaco Agonista de Receptores Nucleares PPARa con Actividad senolítica en pacientes con artrosis de rodilla.
- Expediente: ICI20/00142.
- Entidad financiadora: Proyectos de Investigación Clínica Independiente, ISCIII.
- Duración: 2021-2024.
- Cuantía: 795.300€
- Investigador principal: FJ Blanco.
– Título: Desarrollo de modelos predictivos clínico-moleculares para personalizar la farmacoterapia en artritis reumatoide.
- Expediente: IN607D 2020/10.
- Entidad financiadora: Axencia Galega de Innovación, Xunta de Galicia.
- Duración: 2020-2024.
- Cuantía: 114.870€
- Investigador principal: Cristina Ruiz Romero.
– Título: “EpiOA”
- Proyecto: NIH/NIAMS – OAIBRAC0048
- FUNDING ORGANISATION: NIH (National Institute of Health) USA.
- START DATE AND FINISH DATE: 2021-2022.
- PRINCIPAL INVESTIGATOR: María del Carmen de Andrés González
- BUDGET: Donación de muestras
– TÍTULO: EpiOA: Estudio del papel terapéutico de modificadores epigenéticos y nutracéuticos en la artrosis.
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. AES 2019-ISCIII.
- DURACIÓN: 2020-2022.
- IP: María del Carmen de Andrés González.
- EXPEDIENTE: PI19/01213.
- IMPORTE: 264.082,50 €
– TÍTULO: Eficacia, seguridad y coste-efectividad del metotrexato, adalimumab, o su combinación en uveítis no anterior no infecciosa: un estudio multicéntrico, aleatorizado, paralelo de 3 brazos, con control activo, de fase 3, abierto, con evaluador cegado.
- EXPEDIENTE: ICI19/00020
- ENTIDAD FINANCIADORA: Convocatoria de Proyectos de Investigación Clínica Independiente, ISCIII
- DURACIÓN: 2020-2023
- IP: Luis Rodríguez Rodriguez, Fundacion Investigacion Biomedica Hospital Clinico San Carlos
- IP (GIR): Valentina Calamia
- IMPORTE: 933.308,27
– TÍTULO DEL PROYECTO: Clinical validation of new predictive biomarkers for diagnosis and prognosis in osteoarthritis: HPP project.
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. AES 2019-ISCIII. Expediente: PI19/01206
- DURACIÓN DESDE: 2020 hasta: 2022
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García
- IMPORTE: 215.318€
– TÍTULO DEL PROYECTO: CIBER-BBN (Centro de Investigación Biomédica en Red- Programa Bioingeniería, Biomateriales y Nanomedicina).
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III.
- EXPEDIENTE: CB06/01/0040
- INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero (INIBIC)
- DURACIÓN DESDE:
- IMPORTE:
– Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fenofibrate, a PPARa agonist acting as a Senolytic drug, in Patients with Knee Osteoarthritis
- Original title: Estudio Clínico Fase 2, Randomizado, Controlado por Placebo, Doble-ciego para Evaluar la Eficacia y la Seguridad de Fenofibrato, Fármaco Agonista de Receptores Nucleares PPARa con Actividad
- Funding Agency: Proyectos de Investigación Clínica Independiente, ISCIII
- Reference: ICI20/00142
- Dates: 01/01/2021-31/12/2024
- Budget: 795.300€
- Principal Investigador: Francisco J Blanco
- Members of team involved: Beatriz Caramés, Natividad Oreiro, María Teresa Silva, Iria Ferreño, Ruth Vila, Emma Rodríguez
- Abstract: The purpose of this Phase II clinical trial is to investigate the efficacy and safety of FN in patients with Knee OA. We propose the following aims: 1) to assess clinical efficacy and safety of FN at improving joint pain and function in patients with knee OA 2) to assess the effects of FN on the quality of life in patients with knee OA. In overall, this project aims to define the basis to repurpose FN into a novel therapy for patients with knee OA.
– Title: Advancing PPARα agonists as a Disease-Modifying Therapy for Osteoarthritis
- Original title: Agonistas de PPARa como tratamiento modificador de la enfermedad para la Artrosis
- Funding Agency: Proyectos de Investigación en Salud, AES2020, ISCIII
- Reference: PI20/00643
- Dates: 01/01/2021-31/12/2023
- Budget: 117.370€
- Principal Investigador: Beatriz Caramés Pérez
- Members of team involved: Antonio Pinto Tasende, Patricia Díaz, Tamara Hermida Gómez, Iria Ferreño Rabuñal, Martin Lotz (Scripps Institute)
- Abstract: The purpose of this project is to demonstrate the value of PPARα against as a disease-modifying OA therapy. For this, we aim to: evaluate the clinical impact of PPARα activation in OA patients, assess the efficacy of PPARα activation in translational models of OA and finally, elucidate the hallmarks of joint aging and OA prevention by targeting PPARα. In overall, this project will support evidence for PPARα as an emerging therapeutic target for OA and provide the basis for a clinical trial.
– Title: Identification of osteoarthritis-specific mtDNA mutations through massive sequencing to assess its impact as future therapeutic targets and in the diagnosis of phenotypes.
- Original Title: Identificación de mutaciones de ADNmt específicas de artrosis mediante secuenciación masiva para valorar su impacto como futuras dianas terapéuticas y en el diagnóstico de fenotipos.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI20/00614 Dates: 01/01/2021- 31/12/2023 Budget: 196.020€.
- PI: Ignacio Rego Pérez and Co-PI: Natividad Oreiro Villar.
- Members of team involved: Tamara Hermida Gómez, Alejandro Durán Sotuela, Elisabeth Lamas Rivero.
- Abstract: The main goals of the project are the search of somatic mutations in mitochondrial DNA cartilage-specific and the identification of mitochondrial genetic markers that allow the definition of a metabolic phenotype for OA, applying techniques of massive sequencing in patients from PROCOAC cohort.
– Title: Novel methodologies for osteoarthritis (OA) patient stratification based on proteomics, machine learning and big data.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI20/01409 Dates: 01/01/2021 – 31/12/2023 Budget: 147.620€.
- PI: Valentina Calamia and Co-PI: Mercedes Freire González.
- Members of team involved: Patricia Fernández, Maria Teresa Silva Díaz, Elisabeth Lamas Rivero.
- Abstract: The main goal is to discover and validate specific molecular signatures useful for patient stratification in a cohort of OA individuals with associated comorbidities by proteomics, and finally to develop predictive models based on selected molecular, clinical and phenotypic features by machine learning and Big Data approach.
– Title: Development of integrated predictive analytics solutions to personalize pharmacotherapy in patients with rheumatoid arthritis (BIORESTER-2).
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI20/00793 Dates: 01/01/2021- 31/12/2023 Budget: 140.580€.
- PI: Cristina Ruiz Romero and Co-PI: Antonio Atanes.
- Budget: 147.620€
- Members of team involved: Patricia Fernández, Lucía Lourido, Elena García Moreno, Iria Ferreño.
- Abstract: Rheumatoid arthritis (RA) is one of the most prevalent chronic rheumatic diseases and it is highly disabling. Current therapeutic strategies greatly improve the quality of life of the patient. However, selection from the wide range of available disease modifying agents (DMARDs) is still done through trial and error strategies. This project aims to integrate molecular data obtained from the proteomic analysis of different cohorts of RA patients and to obtain, by these means, clinical-molecular predictive models to facilitate the establishment of precision medicine strategies in patients with RA.
– Title: Development and clinical validation of an early OA diagnosis kit.
- Original Title: Desarrollo y validación clínica de un kit para el diagnóstico precoz de la artrosis.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: DTS17/00200 Dates: 01/01/2018- 31/12/2019 Budget: 75.350€
- PI: Francisco Javier Blanco García.
- Members of team involved: Natividad Oreiro; Cristina Ruiz Romero; Patricia Fernández Puente; Valentina Calamia; Elena Fernández Burguera.
- Abstract: The project proposes the development and clinical validation of a kit for the early diagnosis of OA. This kit is based on suspension beads arrays capable of analyzing simultaneously a panel of 20 circulating proteins with potential OA-biomarker value that have been previously identified by our group. The project will initially develop a semi-quantitative multiplex analysis kit, which will be evaluated in a blind analysis on sera from the PROCOAC cohort, and then the best candidates will be selected for a final quantitative kit that will be validated for clinical use in samples from the incidence cohort of the OsteoArthritis Initiative (OAI).
– Title: Identification of mitochondrial genetic markers of rapid progression of knee OA by next generation sequencing techniques.
- Original Title: Identificación de marcadores genéticos mitocondriales de progresión rápida de artrosis de rodilla mediante técnicas de secuenciación masiva.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI17/00210 Dates: 01/01/2018- 31/12/2020 Budget: 212.657,50 €
- PI: Ignacio Rego Pérez.
- Members of team involved: Ignacio Rego Pérez, Mercedes Fernández Moreno, Natividad Oreiro Villar, Juan Fernández Tajes, Morena Scotece, Elisabeth Lamas Rivero, Alejandro Durán Sotela.
- Abstract: There are OA patients that remain relatively stable over time whilst others progress in a rapid and severe way, achieving a rapid increase of their KL grade in less than 48 months (rapid progressors). Mitochondrial haplogroups condition the rate of incidence and progression of OA, however, the influence of the mitochondrial genetics, as well as the consequences of its interactions with nuclear polymorphisms, in the rate of rapid progression is unknown. Therefore, the aim of this study is to identify mitochondrial genetic variants related to rapid progression in a prospective cohort of OA patients by means of next generation sequencing techniques and to explore potential interactions between mitochondrial polymorphisms and the most robust nuclear polymorphisms related to OA susceptibility.
– Title: Identification and validation of circulating predictive biomarkers of response to biological therapy strategies in patients with rheumatoid arthritis (BIO-RESTER).
- Original title: Identificación y validación de biomarcadores circulantes predictivos de respuesta a estrategias de terapia biológica e pacientes con artritis reumatoide. (BIO-RESTER).
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI17/00404 Dates: 01/01/2018- 31/12/2020 Budget: 123.420 €
- PI: Cristina Ruiz Romero.
- Members of team involved: Patricia Fernández, Carlos Fernández, Carmen Bejerano, Lucía Lourido, Flor Picchi.
- Abstract: This project proposes to carry out a proteomic approach to identify and validate circulating biomarkers predictive of therapeutic response, which can be useful for the selection and optimization of biological therapies. These markers will be combined with other genetic and clinical data to obtain a predictive tool that can be used in clinical practice. The A Coruña Hospital cohort (PROCOAC) and preliminary data from GIR will be used for the identification of markers for therapy selection. Samples from the REMRABIT personalized medicine project will be employed for the identification of therapy optimization markers.
– Title: Identification and Validation of Therapeutic Targets in Diabetes-Associated OA: Role of Autophagy.
- Original Title: Identificación y validación de dianas terapéuticas en la artrosis asociada a diabetes: papel de la autofagia.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI17/02059 Dates: 01/01/2018- 31/12/2020 Budget: 111.320 €
- PI: Beatriz Caramés Pérez.
- Members of team involved: Jose Antonio Pinto Tasende, Uxía Nogueira Recalde, Noa Goyanes Rey, Elena Gismero Salmenor.
- Abstract: In Aging and Osteoarthritis (OA), defects in cellular homeostasis, and in particular in autophagy, precede joint damage. OA is a complex and multifactorial disease, where systemic metabolic status plays a key role. In this sense, patients with Type 2 Diabetes (T2D) present more prevalent and severe OA, so it has been proposed as a new clinical phenotype. However, the mechanisms that define this effect are not fully understood. We have recently shown that there is a decrease in autophagy in chondrocytes and cartilage from patients with OA and T2D. These data suggest that the joint damage presented by patients with OA and T2D could be due to a failure of autophagy, provoking an accumulation of cellular products related to inflammatory and metabolic mediators. These observations represent a unique opportunity to identify and validate biomarkers associated with autophagy and could facilitate the development of therapeutic strategies to prevent joint damage associated with T2D.
– Title: Determination of predictive scores for the diagnosis and prognosis of knee osteoarthritis by the validation of protein biomarkers.
- Original Title: Determinación de índices predictivos de diagnóstico y pronóstico de artrosis de rodilla mediante la validación de biomarcadores protéicos.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI16/02124 Dates: 01/01/2017 – 31/12/2020 Budget: 224.152,50 €
- PI: Francisco Javier Blanco García.
- Members of team involved: Valentina Calamia, Natividad Oreiro, Patricia Fernández, Lucía Lourido.
- Abstract: This project aims to validate a panel of 20 proteins with potential biomarker utility for osteoarthritis in two independent cohorts: the American cohort (OAI) and the cohort from Hospital Universitario de A Coruña (PROCOAC). To perform this validation, two complementary targeted proteomics techniques will be used: mass spectrometry (MRM assays) and antibody microarrays. The use of these techniques on the incidence and progression subcohorts of OAI, and the subsequent external validation of the results in the PROCOAC cohort, would allow selecting the best biomarker candidates and obtaining predictive scores for diagnosis and prognosis of OA, with wide applicability in clinic.
– Title: Identification of Clinical Phenotypes on Osteoarthritis Disease through Big Data Approach.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PIE16/00054 Dates: 01/01/2017 – 30/06/2021 Budget: 523.820,00 €
- PI: Francisco Javier Blanco García.
- Members of team involved: Ignacio Rego Pérez, Sara Relaño Fernández, Elena F Burguera.
- Abstract: OA causes significant comorbidity leading to the simultaneous manifestation of chronic, inflammatory and related diseases in the same patient. Here we aim to design a Biomedical Platform of Knowledge by means of Big Data analysis to integrate clinical and molecular information from well-characterized collections of samples from different cohorts (HIV, Rheumatic, Metabolic and Cardiovascular Disease). The designed platform will allow a comprehensive analysis of all available data to identify unknown OA clinical phenotypes, evaluate mtDNA haplogroups and mitochondrial dysfunction as potential biomarkers and to characterize OA phenotypes with an enhanced inflammatory scenario that takes place under concomitant psoriasis and/or HIV infection.
– Title: Clinical validation of genetic markers to predict persistent remission in rheumatoid arthritis patients treated with biological therapy (REMRABIT).
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PMP15/00032 Dates: 01/01/2016 – 31/12/2020 Budget: 980.305,70 €
- PI: Francisco Javier Blanco García.
- Members of team involved: Natividad Oreiro Villar; Jesús Carlos Fernández López; María Carmen Bejerano Herrería; Elena Gismero Salmador; Ignacio Rego Pérez; Elena F Burguera.
- Abstract: The goal of this project is to calculate the predictive value of 15 reported genetic polymorphisms (SNPs) associated with clinical remission in patients with Rheumatoid Arthritis (RA) treated with biological therapy. It is concurrently performed with a RCT conducted by the Rheumatology Service: “Evaluation of the clinical usefulness of standardized strategies for dose reduction protocol in patients with RA in clinical remission treated with biological therapies: Opened, randomized controlled and non-commercial study”. An associated multicenter sub-study was designed to include 400 patients. Analysis of the genetic background and other clinical variables of responders and non-responders will result in an algorithm to predict clinical remission.
– Title: Clinical validation of new predictive biomarkers for diagnosis and prognosis in osteoarthritis: HPP project
- Funding Agency: Ministerio Ciencia, Innovación y Universidades, Instituto de Salud Carlos III, Strategic Actions in Health 2019
- Reference: PI19/01206 Dates: 01/01/2020- 31/12/2022 Budget: 215,380 €
- PI: Francisco J Blanco
- Members of team involved: FJ Blanco, MT Silva Díaz, R Paz
- Abstract: This project aims to validate a panel of 7 proteins (ORM1; CRAC1; CILP1; CHI3L2; HRG; MGP; and VTDB) with potential biomarker utility for OA in two independent cohorts: the OAI cohort and Hospital Universitario de A Coruña cohort – PROCOAC. To perform this validation complementary targeted proteomics techniques will be used: mass spectrometry (MRM assays) and antibody microarray in suspension beads; these will allow selecting the best biomarker candidates and obtaining predictive scores for diagnosis and prognosis of OA, with wide applicability in clinic.
–Title: Evaluation of the therapeutic potential of epigenetic modifiers and nutraceutics in osteoarthritis. Acronym: EpiOA
- Original Title: Estudio del papel terapéutico de modificadores epigenéticos y nutracéuticos en la artrosis
- Funding Agency: Ministerio Ciencia, Innovación y Universidades, Instituto de Salud Carlos III, Strategic Actions in Health 2019
- Reference: PI19/01213 Dates: 01/01/2020- 31/12/2022 Budget: 264,082.50 €
- PI: María del Carmen de Andrés González
- Members of team involved: T Hermida-Gomez, C Fernández-López; RO Oreffo
- Abstract: This project aims to understand how epigenetic modifiers, taken either as drugs or together with the diet, affect OA progression, so that they can be used to treat patients. In a first approach, human chondrocytes will be treated with a range of chemicals that potentially can modulate epigenetic control in OA to study the expression of OA genes-related that correlate with epigenetic changes. Identified prospective chemicals will be tested in an OA mice model. Then, epigenetic markers detected will be correlated in samples from the OAI cohort that have demonstrated that adherence to the Mediterranean diet is associated with better quality of life and lower OA prevalence.
– Title: Efficacy, safety and cost-effectiveness of monotherapy with either Methotrexate or Adalimumab or a combination therapy with both drugs: a multicentric study.
- Original Title: Eficacia, seguridad y coste-efectividad del metotrexato, adalimumab, o su combinación en uveítis no anterior no infecciosa: un estudio multicéntrico, aleatorizado, paralelo de 3 brazos, con control activo, de fase 3, abierto, con evaluador cegado.
- Funding Agency: Ministerio Ciencia, Innovación y Universidades, Instituto de Salud Carlos III, Independent Clinical Trials 2019
- Reference: ICI19/00020 Dates: 01/01/2020- 31/12/2023 Budget: 933,308.27€
- PI: Luis Rodríguez Rodríguez, Fundacion Investigacion Biomedica Hospital Clínico San Carlos
- GIR Partner PI: Valentina Calamia
- Members of team involved: P Fernández-Puente
- Abstract: The overall objective is to evaluate the efficacy, safety and cost-effectiveness of monotherapy with either Methotrexate or Adalimumab (Humira®) or a combination therapy with both drugs. Additionally, we will identify patient’s subgroups with different treatment responses, by developing prediction models based on machine learning techniques using genetic and proteomic biomarkers.
AUTONOMIC
– Title: Pharmacogenetics study to predict the response to Tocilizumab in SARS-CoV-2 infected patients
- Original title: Estudio farmacogénetico para predecir la respuesta al Tocilizumab en pacientes infectados por SARS-CoV-2
- Funding Agency: Convocatoria para proxectos de investigación sobre o SARS-CoV-2 e a enfermidade COVID-19, GAIN, Xunta de Galicia
- Reference: –
- Dates: 30/11/2020 – 31/12/2022
- Budget: 133.130€
- Principal Investigador: Ignacio Rego Pérez
- Members of team involved: Sara Relaño Fernández, Alejandro Durán Sotuela, Paula Ramos Louro, Mercedes Fernández Moreno
- Abstract: The main goal of this project is to apply massive sequencing techniques to identify genetic markers for the response to treatment in patients infected with SARS-CoV-2 that develop a severe bilateral pneumonia.
– Title: Consolidation and Structuring Program of Units of Competitive Research. Grants for research staff with excellent track record.
- Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación.
- Reference: IN607D2020/10 Dates: 01/10/2020 – 31/12/2024 Budget: 114.870€.
- PI: Cristina Ruiz Romero.
- Members of team involved: Antonio Atanes, Patricia Fernández, Lucía Lourido, Elena García Moreno, Iria Ferreño.
PRIVATE FUNDING
– Title: Characterization of Rapid Knee OA Progression Phenotypes
- Funding Agency: Investigator Sponsored Research, Pfizer Independent Research Grants, Pfizer
- Reference: ID#61749193
- Dates: 01/11/2020-31/10/2021
- Budget: 47.136€
- Principal Investigator: Francisco J Blanco
- Members of team involved: Ignacio Rego Pérez, Juan Fernández Tajes
- Abstract: Characterization of rapidly progressive (radiographic and symptomatic) knee osteoarthritis phenotypes using (clinical and analytical) data from two large OA cohorts, the American cohort OAI and the Spanish cohort PROCOAC.
– Title: Chair in Tissue Engineering and Cell Therapy.
- Funding Body: BIOIBERICA S.A.
- Abstract: FJ Blanco holds the Chair in “Tissue Engineering and Cell Therapy” established in 2005, at the University of A Coruña, by BIOIBERICA S.A. The objectives of this Chair are: to analyze therapeutic value of chondroprotection in Osteoarthritis. Bioiberica is a biotechnology company specialized in the identification and extraction of biomolecules of high biological and therapeutic value from tissues of animal origin. Bioiberica is the leading Western producer of heparin and leader in Osteoarthritis and joint health for people and animals. This ongoing collaboration has resulted in a licensed product and more than 15 peer-reviewed scientific publications.
OTHER PROJECTS
INTRAMURALES:
– TÍTULO DEL PROYECTO: Development of a targeted proteomics method to improve the diagnostic accuracy of cardiac amyloidosis and facilitate precision medicine approaches (CAMS Project).
- DURACIÓN: 01/01/2021-31/12/2023.
- COORDINADOR/INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero.
- COLABORADORES: Marisa Crespo, INIBIC (CIBER-CV).
– Title: Innovative Platforms for Radiopharmaceutical Applications
- Original title: Plataformas Innovadoras para Aplicaciones Radiofarmacéuticas
- Funding Agency: Ministerio de Ciencia e Innovación
- Reference: PID2019-111388GB-I00
- Principal Investigador: Carlos Platas Iglesias, David Esteban Gómez, UDC
- Dates: 01/06/2020-31/05/2023
- Budget: 121.000€
- Members of GIR team involved: Tamara Hermida Gómez
GRANTED IN 2021
– Título: Axudas para a consolidación e estruturación de unidades de investigación competitivas, modalidade A-Grupos de referencia competitiva.
- Expediente: IN607A2021/07.
- Entidad financiadora: Axencia Galega de Innovación, Xunta de Galicia.
- Duración: 2021-2024.
- Cuantía: 400.000€
- Investigador principal: Francisco J Blanco.
– Título: Identificación de mutacións de ADNmt específicas da artrose mediante secuenciación masiva para valorar o seu impacto como futuras dianas terapéuticas e no diagnóstico do fenotipo metabólico nunha cohorte de pacientes de Galicia.
- Expediente: IN607D 2021/13.
- Entidad financiadora: Axudas para a consolidación e estruturación de unidades de investigación competitivas e outras acción de fomento. Modalidade C-Proxectos de excelencia. Axencia Galega de Innovación, Xunta de Galicia.
- Duración: 2021-2025.
- Cuantía: 115.000€
- Investigador principal: Ignacio Rego Pérez.
– TÍTULO: Red en Enfermedades Inflamatorias – REI.
- EXPEDIENTE: RD21/0002/0009.
- ENTIDAD FINANCIADORA: Redes de Investigación Cooperativa Orientadas al Resultado en Salud (RICORS), ISCIII.
- DURACIÓN: 2022-2024.
- CUANTÍA: 99,156€
- INVESTIGADOR PRINCIPAL: FJ Blanco.
– TÍTULO: Osteoartritis: investigación sobre el colágeno y nuevos ingredientes bioactivos.
- EXPEDIENTE:
- ENTIDAD FINANCIADORA: Centro para el Desarrollo Tecnológico Industrial (CDETI). Proyectos I+D Transferencia Cervera. Ministerio de Ciencia e Innovación.
- PARTICIPANTES: Ordesa, Leitat, AINIA, Gaiker e INIBIC.
- DURACIÓN: 2022-2014.
- CUANTÍA: 111.925€
- INVESTIGADOR PRINCIPAL: Beatriz Caramés Pérez.
- REQUESTED PROJECTS PENDING RESOLUTION:
– Title: Epigenetic profiling to define molecular transition from remission to flare (Acronym: EpiFlare).
- Convocatoria: Call for research proposals on Remission and Flare, FOREUM (Foundation for Research in Rheumatology).
- IP: Dr. Bruno Stuhlmüller.
- Budget: 600.000€
- No concedido.
PREVIOUS GIR PROJECTS:
INTERNATIONAL
NATIONAL
AUTONOMIC
OTHER PROJECTS
ISCII NETWORK
⊗
INTERNATIONAL
– Title: Targeting senescent cells in osteoarthritis: an innovative therapeutic approach. Acronym: SEN-OA
- Funding Agency: Foundation for Research in Rheumatology (FOREUM)
- Reference: SEN-OA
- Dates: 01/06/2018- 31/12/2021
- Budget: 600.000€
- PI: Daniele Nöel, INSERM
- GIR Partner PI: Bea Caramés (WP4 Leader)
- Website: http://www.foreum.org/sen_oa.cfm
- Members of team involved: Uxía Nogueira Recalde, Irene Lorenzo Gómez
- Abstract: The main risk factor for Osteoarthritis (OA) is ageing. An emerging concept for age-related diseases is that senescent cells accumulate with time and release SASP(senescence-associated secretory profile) products, which alter tissue functions. Accumulation of senescent cells during lifespan is believed to contribute to progressive tissue loss of functions. Specific elimination of these cells could prevent some age- associated diseases.
– Title: Studies of Joint Aging and Osteoarthritis.
- Funding Agency: National Institute of Aging / National Institute of Health.
- Dates: 01/04/2009- 03/04/2020
- Budget: $11.832.399
- PI: Martin Lotz.
- GIR Partner PI: Beatriz Caramés.
- Members of team involved: 1.
- Abstract: The overall goal of this program is to begin with phenotype identification, proceed to elucidation of mechanisms and key cellular and molecular abnormalities in order to provide new directions for correction of aging-associated risk factors for OA and therapeutic interventions for established OA. In this project we focus on the identification of early changes in cellular and joint homeostasis mechanisms upon which OA is triggered or accelerated in response to biomechanical or biochemical stressors.
– Title: Applied public-private research enabling osteoarthritis clinical headway (APPROACH).
- Funding Agency: EU – IMI/ EFPIA.
- Reference: IMI-115770-2-APPROACH
- Dates: 01/06/2015 – 30/11/2021
- Budget: €17.5M
- PI: Jonathan Larkin (GlaxoSmithKline, United Kingdom, Coordinator) & Harrie Weinans (UMC Utrecht, The Netherlands, managing entity).
- GIR Partner PI: Francisco Javier Blanco García.
- Website: https://www.approachproject.eu/
- Members of team involved: Joana Magalhaes, Cristina Ruiz Romero, Ignacio Rego, Natividad Oreiro, Carlos Tilve.
- Abstract: The APPROACH project brings together European clinical centers, basic research institutes, small- and medium-sized businesses and pharmaceutical companies. Together, they will combine biomedical data from more than 10.000 people with and without osteoarthritis into a unified bioinformatics platform with the aim of identifying different OA phenotypes. These phenotypes will then be validated in a longitudinal cohort using existing and newly-developed biomarkers. This will allow for the development of guidelines for differentially diagnosing the right patient for the right treatment.
– Title: Mitochondrial mapping: Evolution-Age-Gender-Lifestyle-Environment (MITOEAGLE).
- Funding Agency: EU – Cost Actions.
- Reference: CA15203 Dates: 12/09/2016-11/09/2020
- PI: Erich Gnaiger, Medical University of Innsbruck, Austria.
- GIR Partner PI: Francisco Javier Blanco García.
- Website: http://www.mitoglobal.org/index.php/MITOEAGLE
- http://www.cost.eu/COST_Actions/ca/CA15203
- Abstract: The objective of MITOEAGLE network is to improve our knowledge on mitochondrial function in health and disease related to Evolution, Age, Gender, Lifestyle and Environment. Every study of mitochondrial (mt) function and disease is faced with EAGLE as the essential background conditions characterizing the individual patient, subject, study group, species, tissue or even cell line. To address the complex interrelationships of EAGLE with an initial focus on humans and rodent models, the network will enhance the value of each individual study by starting to analyse and catalog data beyond the published record. Highlighting the topic of gender and mitochondrial function, unique new information will emerge on human biology from the development of a European reference database.
– Título: Characterization of Rapid Knee OA Progression Phenotypes.
- Expediente: ID#61749193.
- Convocatoria: Pfizer Independent Research Grants, Pfizer.
- Investigador principal: Francisco J Blanco.
- Importe: 47.136€
- Duración: 01/11/2020-31/10/2021.
- Objetivos: Characterization of rapidly progressive (radiographic and symptomatic) knee osteoarthritis phenotypes using (clinical and analytical) data from two large OA cohorts, the American cohort OAI and the Spanish cohort PROCOAC.
– Título del proyecto: Applied public-private research enabling osteoarthritis clinical headway (APPROACH).
- Expediente: IMI-115770-2.
- ENTIDAD FINANCIADORA: Innovative Medicine Initiative – Unión Europea.
- DESDE: 2015-2020 (Prórroga hasta: 30/11/2021).
- Coordinador: Harrie Weinans (UMC Utrecht, The Netherlands).
- Nombre del IP: Francisco J. Blanco.
- Importe: 660.000€
– TITULO DEL PROYECTO: Mitochondrial mapping: Evolution – Age – Gender – Lifestyle – Environment (COST).
- ENTIDAD FINANCIADORA: Union Europea. Programa COST Action CA15203.
- DURACIÓN DESDE: 12/09/2016 – HASTA: 11/09/2020.
- Coordinador: Prof Erich GNAIGER (AT).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
– TITULO: SEN-OA – Targeting senescent cells in osteoarthritis: an innovative therapeutic approach.
- ENTIDAD FINANCIADORA: Foundation for Research in Rheumatology (Foreum).
- DURACIÓN: 2017-2020.
- Project Coordinator: Daniele Noel, INSERM, Montpellier, Francia.
- IP (WP 4 leader): Beatriz Caramés.
- FINANCIACIÓN: 600.000€
- CUANTÍA GRUPO GIR: 83.000€
- EXPEDIENTE: SEN-OA
– Título: “Circulating mtDNA as a potential biomarker of osteoarthritis progression”. NIH/NIAMS – OAIBRAC0039:
- FUNDING ORGANISATION: NIH (National Institute of Health) USA.
- START DATE AND FINISH DATE: 2018-2020.
- PRINCIPAL INVESTIGATOR: Blanco García F.J.
– Título: “Characterization of rapid progression phenotype of knee OA: association with mtDNA haplogroups”.
- proyecto NIH/NIAMS – OAIBRAC0006.
- FUNDING ORGANISATION: NIH (National Institute of Health) USA.
- START DATE AND FINISH DATE: 2018-2020.
- PRINCIPAL INVESTIGATOR: Blanco García F.J. BUDGET: ——-
– Title: Bioengineering Networking Institute for Health Aging (IBEROS).
- Funding Agency: EU – Interreg Spain-Portugal, POCTEP.
- Reference: 0245_IBEROS_1_E Dates: 01/10/2015-31/09/2019 Budget: €1.46M
- PI: Pío González Fernández, University of Vigo.
- GIR Partner PI: Joana Cristina Silva Magalhaes.
- Website:
- Members of team involved: Joana Magalhaes, Elena F. Burguera, Paula Casal Beiroa, Noa Goyanes Rey, Tamara Hermida, Natividad Oreiro.
- Abstract: IBEROS is a networking interdisciplinary center formed by 13 groups from 8 entities from the North of Portugal and Galicia. The main goal is to promote research and innovation in the areas of Bioengineering (Biomaterials, Nanotechnology and Biosensors) to accomplish technological solutions that contribute to improve the quality of life and health of the population, specially focused on aging-associated diseases. GIR main activity in this project is to discover optical biomarkers for the early diagnosis of OA and new marine drugs with chondrogenic activity.
- OAI Studies
- The Osteoarthritis Initiative (OAI) is a public-private partnership that provides new resources and commitment to help find biochemical, genetic and imaging biomarkers for onset and progression of knee OA. The OAI cohort study has a public archive of data, biological samples and joint images collected over time from a clinically well characterized population of individuals. Participants are followed for ten years for changes in the clinical status of the knee and other joints.
- Website: https://oai.epi-ucsf.org
– Title: Circulating mtDNA as a potential biomarker of osteoarthritis progression.
- Funding Agency: NIH/NIAMS (USA)
- Reference: OAIBRAC0039
- Dates: 01/01/2018- 31/12/2020
- PI: FJ Blanco
- Members of team involved: Ignacio Rego-Pérez, Morena Scotece
- Abstract: The objective of this project is to quantify the circulating mtDNA in serum of OAI cohort subjects with Caucasian ancestry in order to determine its potential role as a biomarker of OA progression and /or incidence.
– Title: Characterization of rapid progression phenotype of knee OA: association with mtDNA haplogroups.
- Funding Agency: NIH/NIAMS (USA)
- Reference: OAIBRAC0006
- Dates: 01/01/2018- 31/12/2020
- PI: FJ Blanco
- Members of team involved: Ignacio Rego-Pérez, Alejandro Durán-Sotuela
- Abstract: There is a pressing need to study individuals with accelerated knee OA to determine if these individuals can be identified, a prerequisite if we to include them in trials to implement prevention strategies. In addition, the identification of this specific phenotype (rapid Progression) is a priority research line proposed by the EULAR committee of OA researchers. The main goal is to identify specific mitochondrial genetic polymorphisms able to predict a rapid progression phenotype in patients from the OAI.
NATIONAL
– Título: Influencia del ADN mitocondrial en la infección por el SARS-COV-2 y en los perfiles clínicos del COVID19 (MITO-COVID19).
- Expediente: CT850A-10.
- Agencia financiadora: Convocatoria Traslaciona COVID19. ACIS.
- Duración: 2020-2021.
- Presupuesto: 73.848€
- IP: FJ Blanco.
– TÍTULO: Sondas Ópticas para IMagen MOlecular en cultivos CELulares- IMMOCEL.
- ENTIDAD FINANCIADORA: Convocatoria Proyectos Semilla-Agrupación Estratégica CICA-INIBIC.
- DURACIÓN: 01/10/2019-30/10/2020.
- IPs: Tamara Hermida Gómez y David Esteban Gómez.
- IMPORTE: 5.000€
– TÍTULO DEL PROYECTO: Clinical validation of genetic markers to predict persistent remission in rheumatoid arthritis patients treated with biological therapy (REMRABIT).
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. Expediente PMP15/00032.
- DURACIÓN DESDE: 2016 HASTA: 2019 (Prórroga hasta 31/12/2021).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 980.305,70 €
– TÍTULO DEL PROYECTO: Determinación de índices predictivos de diagnóstico y pronóstico de artrosis de rodilla mediante la validación de biomarcadores protéicos.
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. Expediente PI16/02124.
- DURACIÓN DESDE: 2017 HASTA: 2019 (Prórroga hasta 30/06/2021).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 224.152,50 €
– TÍTULO DEL PROYECTO: Identification of clinical phenotypes on Osteoarthritis (OA) disease through Big Data approach. (PROYECTO EXCELENCIA).
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. Expediente PIE16/00054.
- DURACIÓN DESDE: 2017 HASTA: 2019 (Prórroga hasta 30/06/2021).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 523.820,00 €
– TÍTULO DEL PROYECTO: Desarrollo y validación clínica de un kit para el diagnóstico precoz de la artrosis.
- ENTIDAD FINANCIADORA: Fondo de Investigación Sanitaria. Expediente: DTS17/00200.
- DURACIÓN DESDE: 2018 HASTA: 2019 (Prórroga hasta 31/12/2020).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 75.350€
– TÍTULO DEL PROYECTO: Red de Inflamación y enfermedades reumáticas (Redes Temáticas de Investigación Cooperativa en Salud)- RIER.
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. Expediente RD16/0012/0002.
- DURACIÓN DESDE: 2017 HASTA: 2021.
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 168.624,50€
– TITULO DEL PROYECTO: Identificación de marcadores genéticos mitocondriales de progresión rápida de artrosis de rodilla mediante técnicas de secuenciación masiva.
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/00210.
- DURACIÓN: 2018-2020.
- INVESTIGADOR PRINCIPAL: Ignacio Rego Pérez.
- FINANCIACIÓN: 212.657,50 €
– TITULO: Identificación y validación de biomarcadores circulares predictivos de respuesta a estrategias de terapia biológica en pacientes con artritis reumatoide (BIO-RESTER).
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/00404.
- DURACIÓN: 2018-2020 (prórroga hasta 30/06/2022).
- INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero.
- FINANCIACIÓN: 123.420 €
– TITULO: Identificación y validación de dianas terapéuticas en la artrosis asociada a diabetes: Papel de la autofagia.
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. EXPEDIENTE: PI17/02059.
- DURACIÓN: 2018-2020.
- INVESTIGADOR PRINCIPAL: Beatriz Caramés Pérez.
- FINANCIACIÓN: 111.320 €
– TÍTULO DEL PROYECTO: Plataforma de Proteómica, Genotipado y Líneas Celulares.
- ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. Expediente: PT17/0019/0014.
- DURACIÓN DESDE: 2018 HASTA: 2020 (prorrogado hasta 31/12/2021).
- INVESTIGADOR PRINCIPAL: Francisco Javier Blanco García.
- IMPORTE: 110.550€
– Title: Design of a celular model usign transmitochondrial cybrids for the discovery of epigenetic biomarkers for the diagnosis of different OA phenotypes.
- Original Title: Diseño de un modelo celular de cíbridos transmitocondriales para la búsqueda de biomarcadores epigenéticos para el diagnóstico de distintos fenotipos de artrosis.
- Funding Agency: Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01254 Dates: 01/01/2015- 31/12/2017 Budget: 86.515 €
- PI: Ignacio Rego Pérez
- Members of team involved: Mercedes Fernández Moreno, Natividad Oreiro Villar, María Eugenia Vázquez Mosquera, Sara Relaño, Juan Fernández Tajes.
- Abstract: Methylation is a dynamic process prone to changes in the environment also involved in the phenotypic modulation that articular chondrocytes undergo during OA. In addition, nutrition and obesity are OA risk factors associated with alterations in DNA methylation. Mitochondria are involved in OA and modulate the DNA methylome, consequently the analysis of DNA methylome is a powerful tool to identify new OA biomarkers. The aim of this work is to create a chondrocyte-based cellular model of cytoplasmic cybrids to analyze the differential methylome, from exposure to oxidative stress, diet and inflammatory stimuli on different mitochondrial backgrounds to design a classifier that allow the identification of different OA phenotypes.
– Title: Validation of osteoarthritis protein biomarkers using targeted proteomics for the development of an in vitro diagnostic test.
- Original Title: Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01707 Dates: 01/01/2015- 31/12/2017 Budget: 134.915€
- PI: Cristina Ruiz Romero
- Members of team involved: Patricia Fernández, Natividad Oreiro, Valentina Calamia, María Camacho, Lucía González, Flor Picchi
- Abstract: The objective of this project is to develop three complementary targeted proteomic techniques in order to validate a panel of 200 protein biomarkers of Osteoarthritis. We will employ the following technologies: 1) targeted mass spectrometry (MRM assays); 2) analytical protein microarrays and 3) hybrid methodologies, involving immunoaffinity enrichment and subsequently mass spectrometry. The use of these techniques on serum and synovial fluid samples will allow validating the best candidates and developing a method for the molecular in vitro diagnosis of osteoarthritis that could be easily translated to the clinical routine and is potentially patentable.
– Title: Targeting Cartilage Aging to Identify Osteoarthritis Therapeutics.
- Original Title: Identificación de moléculas reguladoras del envejecimiento articular para el tratamiento de la artrosis.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01324 Dates: 01/01/2015- 31/12/2018 Budget: 78.226,50€
- PI: Beatriz Caramés Pérez
- Members of team involved: Madalena Ribeiro, María José Sanchez Dopico, Luis Antonio García Rodriguez
- Abstract: Effective treatments for osteoarthritis (OA) are not available. Advances in mechanisms in aging-related diseases, including OA, have led to the concept that the failure of cellular homeostasis mechanisms, such as, autophagy can cause extracellular matrix destruction and cell death. In this sense, pharmacological stimulation of autophagy has anti-aging effects and may promote longevity. Chondrocytes are required for maintenance of cartilage integrity. With aging, chondrocytes function is limited, contributing to an imbalance in anabolic and catabolic activity and induce cellular senescence. These observations provide a unique opportunity to study cartilage aging with the objective to explore the therapeutic potential of pharmacological prevention of chondrocyte senescence and autophagy.
– Title: CICA-INIBIC Consortium.
- Funding Agency: Xunta de Galicia.
- Reference: AGRUP2015/05 Dates: 01/01/2015 – 31/12/2017 Budget: €500.000
- PI: Jaime Rodríguez González (UDC)
- GIR Partner PI: Francisco Javier Blanco García
- Members of team involved: Joana Magalhaes, Elena F. Burguera, Tamara Hermida, Cristina Ruiz Romero, Mercedes Fernández Moreno.
- Abstract: GIR is a founding member of the Strategic Consortium CICA-INIBIC that integrates 23 research groups from both the Advanced Scientific Research Center (CICA) and INIBIC, combining research in areas such as chemistry, biology and basic and clinical biomedical research in which the groups are international referents. Strategic Consortium CICA-INIBIC is defined as a multidisciplinary and synergic environment focused on efficiently address current biomedical, technological and environmental challenges through research, training and comprehensive solutions to generate scientific and economic value, and social progress.
– Title: Design of a celular model usign transmitochondrial cybrids for the discovery of epigenetic biomarkers for the diagnosis of different OA phenotypes.
- Original Title: Diseño de un modelo celular de cíbridos transmitocondriales para la búsqueda de biomarcadores epigenéticos para el diagnóstico de distintos fenotipos de artrosis.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01254 Dates: 01/01/2015 – 31/12/2017 Budget: 86.515 €
- PI: Ignacio Rego Pérez.
- Members of team involved: Mercedes Fernández Moreno, Natividad Oreiro Villar, María Eugenia Vázquez Mosquera, Sara Relaño, Juan Fernández Tajes.
- Abstract: Methylation is a dynamic process prone to changes in the environment also involved in the phenotypic modulation that articular chondrocytes undergo during OA. In addition, nutrition and obesity are OA risk factors associated with alterations in DNA methylation. Mitochondria are involved in OA and modulate the DNA methylome, consequently the analysis of DNA methylome is a powerful tool to identify new OA biomarkers. The aim of this work is to create a chondrocyte-based cellular model of cytoplasmic cybrids to analyze the differential methylome, from exposure to oxidative stress, diet and inflammatory stimuli on different mitochondrial backgrounds to design a classifier that allow the identification of different OA phenotypes.
– Title: Validation of osteoarthritis protein biomarkers using targeted proteomics for the development of an in vitro diagnostic test.
- Original title: Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01707 Dates: 01/01/2015 – 31/12/2017 Budget: 134.915€
- PI: Cristina Ruiz Romero.
- Members of team involved: Patricia Fernández, Natividad Oreiro, Valentina Calamia, María Camacho, Lucía González, Flor Picchi.
- Abstract: The objective of this project is to develop three complementary targeted proteomic techniques in order to validate a panel of 200 protein biomarkers of Osteoarthritis. We will employ the following technologies: 1) targeted mass spectrometry (MRM assays); 2) analytical protein microarrays and 3) hybrid methodologies, involving immunoaffinity enrichment and subsequently mass spectrometry. The use of these techniques on serum and synovial fluid samples will allow validating the best candidates and developing a method for the molecular in vitro diagnosis of osteoarthritis that could be easily translated to the clinical routine and is potentially patentable.
– Title: Identification of Novel Molecules Targeting Cartilage Aging as Osteoarthritis Therapeutics.
- Original Title: Identificación de moléculas reguladoras del envejecimiento articular para el tratamiento de la artrosis.
- Funding Agency: Fondo de Investigación Sanitaria. ISCIII.
- Reference: PI14/01324 Dates: 01/01/2015 – 31/12/2017 Budget: 78.226,50€
- PI: Beatriz Caramés Pérez.
- Members of team involved: 4.
- Abstract: Effective treatments for osteoarthritis (OA) are not available. Advances in mechanisms in aging-related diseases, including OA, have led to the concept that the failure of cellular homeostasis mechanisms, such as, autophagy can cause extracellular matrix destruction and cell death. In this sense, pharmacological stimulation of autophagy has anti-aging effects and may promote longevity. Chondrocytes are required for maintenance of cartilage integrity. With aging, chondrocytes function is limited, contributing to an imbalance in anabolic and catabolic activity and induce cellular senescence. These observations provide a unique opportunity to study cartilage aging with the objective to explore the therapeutic potential of pharmacological prevention of chondrocyte senescence and autophagy.
– Title: CICA-INIBIC Consortium.
- Funding Agency: Xunta de Galicia.
- Reference: AGRUP2015/05 Dates: 2015 – 2017 Budget: €500.000
- PI: Jaime Rodríguez González (UDC).
- GIR Partner PI: Francisco Javier Blanco García.
- Members of team involved: Joana Magalhaes, Elena F. Burguera, Tamara Hermida, Cristina Ruiz Romero, Mercedes Fernández Moreno.
- Abstract: GIR is a founding member of the Strategic Consortium CICA-INIBIC that integrates 23 research groups from both the Advanced Scientific Research Center (CICA) and INIBIC, combining research in areas such as chemistry, biology and basic and clinical biomedical research in which the groups are international referents. Strategic Consortium CICA-INIBIC is defined as a multidisciplinary and synergic environment focused on efficiently address current biomedical, technological and environmental challenges through research, training and comprehensive solutions to generate scientific and economic value, and social progress.
AUTONOMIC
– Title: Rheumatology Research Group (GIR). Group of Excellence.
- Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación.
- Reference: IN607A2017/11 Dates: 01/01/2017 – 31/12/2020 Budget: €330.060
- PI: Francisco J Blanco
- Members of team involved: All Group.
– Title: Galician Network of Colorectal Cancer Research (REGICC).
- Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación
- Reference: ED431D2017/23 Dates: 01/01/2017 – 31/12/2019 Budget: €120.000
- Principal Investigator: Alejandro Pazos (University of A Coruña)
- GIR Partner PI: Francisco J Blanco
- Website: http://regicc.imedir.udc.es/es/sections/Default.aspx
- Members of team involved: All Group.
– Title: Galician Network of Drugs Research and Development (REGID).
- Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación
- Reference: ED431D 2017/16 Dates: 01/01/2017 – 31/12/2019 Budget: €120.000
- Principal Investigator: María Isabel Loza García (Universidade de Santiago de Compostela)
- GIR Partner PI: Francisco J Blanco
- Website: http://regid.cesga.es/
- Members of team involved: All Group.
– Title: Peptide microarray for osteoarthritis diagnosis and monitoring.
- Original Title: Microarray de Péptidos para el Diagnóstico y Monitorización de la Artrosis.
- Funding Agency: Agencia Galega de Innovación, Xunta de Galicia.
- Reference: IN855A 2016/35 Dates: 01/01/2018- 31/12/2019 Budget: 446.500€
- PI: Francisco Javier Blanco García
- Members of team involved: Cristina Ruiz Romero, Patricia Fernandez Puente, Valentina Calamia, Lucía Lourido Salas, Elena Fernández Burguera
- Abstract: The objective of this project is to valorize a panel of 13 peptides (protein fractions), identified and academically validated, for the early diagnosis of osteoarthritis (OA) in human serum. The main output of the project is the licensing of the intellectual property of the panel to a consolidated company in the pharmaceutical sector.
– Title: Influence of mitochondrial DNA in the SARS-COV-2 infection and clinical profiles from COVID-19
- Original title: Influencia del ADN mitocondrial en la infección por el SARS-COV-2 y en los perfiles clínicos del COVID19
- Funding Agency: Convocatoria Traslaciona COVID19. ACIS
- Reference: CT850A-10
- Dates: 01/11/2020 – 31/10/2021
- Budget: 73.848€
- Principal Investigador: Francisco J Blanco
- Members of team involved: Carlos Vaamonde García, Francisco Castiñeira Romar, Pedro Puig Gallego
- Abstract: This project aims to analyze the association of mitochondrial (mt) haplogroups with COVID19, by: identifying EU mt haplogroups in patients with COVID19; studying the influence of EU mt haplogroups on the risk of infection from SARS-CoV-2 virus and studying the influence of EU mt haplogroups on the risk of developing severe COVID19 (pneumonia and pulmonary fibrosis).
TITULO: Ayudas para consolidación y estructuración de unidades de investigación. Grupo Referencia Competitiva Modalidad A.
- ENTIDAD FINANCIADORA: Xunta de Galicia. EXPEDIENTE: IN607A 2017/11.
- DURACIÓN: 2017-2020.
- INVESTIGADOR PRINCIPAL: Blanco García FJ.
- FINANCIACIÓN: 330.060,34€
– Title: CICA-INIBIC Consortium.
- Funding Agency: Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria
- Reference: AGRUP2015/05 Dates: 01/01/2015 – 30/11/2017 Budget: €500.000
- Principal Investigator: Jaime Rodríguez González (Universidade da Coruña)
- GIR Partner PI: Francisco J Blanco
- Members of team involved: Cristina Ruiz Romero, Joana Magalhães, Elena F. Burguera, Tamara Hermida, Natividad Oreiro, Purificación Filgueira, Cristina Rodríguez Pereira, Lucía Gato.
- PRIVATE FUNDING:
- THIS CATEGORY IS UNDER CONSTRUCTION.
OTHER PROJECTS
INTRAMURALES:
– TÍTULO DEL PROYECTO: Tailored Nanopatterning Scaffolds for Musculoskeletal Tissue Regeneration.
- DURACIÓN: 01/01/2018 – 31/12/2021.
- COORDINADOR: Josep Samitier.
- INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero.
– TÍTULO DEL PROYECTO: Development and validation of methods for the evaluation of osteoarthritis-related protein biomarkers useful for its diagnosis, monitoring and therapy 2.
- DURACIÓN: 01/01/2018 – 31/12/2021.
- COORDINADOR / INVESTIGADOR PRINCIPAL: Cristina Ruiz Romero.
– TÍTULO DEL PROYECTO: Osteoarticular Regeneration by Bioprinting.
- DURACIÓN: 01/01/2018 – 31/12/2021.
- COORDINADOR: Luis M. Rodríguez Lorenzo.
- INVESTIGADOR PRINCIPAL: Joana Magalhães.
ISCII NETWORK
THIS CATEGORY IS UNDER CONSTRUCTION.
EditProjects
Girblanco © 2023. All rights reserved.
⊗
